Free Trial

Instil Bio Q1 2023 Earnings Report

Instil Bio logo
$20.97 -0.45 (-2.10%)
As of 01/17/2025 04:00 PM Eastern

Instil Bio EPS Results

Actual EPS
-$8.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Instil Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Instil Bio Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Instil Bio Earnings Headlines

Instil Bio upgraded to Buy from Hold at Jefferies
Must-See: 5-Second Trump Prediction
President Trump's prediction is about to become a reality... Opening a rare window of opportunity for you to accelerate your retirement during the first 100 days of his administration.
Jefferies Upgrades Instil Bio (TIL)
Instil Bio Secures Loan to Refinance Facility
See More Instil Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Instil Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Instil Bio and other key companies, straight to your email.

About Instil Bio

Instil Bio (NASDAQ:TIL), a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

View Instil Bio Profile

More Earnings Resources from MarketBeat